Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction (MBO—IR)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2010 by Tianjin Medical University Cancer Institute and Hospital
Sponsor:
Information provided by (Responsible Party):
Tianjin Medical University Cancer Institute and Hospital
ClinicalTrials.gov Identifier:
NCT01073514
First received: February 21, 2010
Last updated: July 31, 2014
Last verified: February 2010

February 21, 2010
July 31, 2014
December 2009
November 2014   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01073514 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction
Clinical Trial of Bile Etiology,Proteomics and Metabonomics of Malignant Biliary Obstruction

To investigate bile culture and susceptibility test in patients with malignant biliary obstruction (MBO) or relation between bile, portal vein or vein culture and biliary infection. Also to get the information of bile metabonomics to find potential tumor marker .Culture of the organism is recognized as the "gold standard" for diagnosis of infection. Our research may be one of the first research on culture and susceptibility test in patients with MBO. The results of the trial research will be benefit to experiential therapy of MBO with biliary infection and diagnosis of MBO.

We will obtain bile sample for culture and susceptibility ,proteomics metabonomics test after PTBD. Also get the blood and urine samples.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

bile,blood and urine specimen

Probability Sample

Malignant obstructive jaundice (MBO)

Malignant Biliary Obstruction
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
December 2014
November 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Those with MBO who can receive Percutaneous Transhepatic Biliary Drainage(PTBD)

Exclusion Criteria:

  • Those with MBO who cannot receive Percutaneous Transhepatic Biliary Drainage(PTBD)
Both
18 Years to 70 Years
No
Contact: YU HAI PENG, MD 13352070835 JIERUKE@YAHOO.COM.CN
China
 
NCT01073514
TMU-CIH-IR-001, ChiCTR-ONC-00000752
Yes
Tianjin Medical University Cancer Institute and Hospital
Tianjin Medical University Cancer Institute and Hospital
Not Provided
Principal Investigator: YU HAI PENG, MD Tianjin Medical University Cancer Institute and Hospital
Study Chair: GUO ZHI, Professor Tianjin Medical University Cancer Institute and Hospital
Tianjin Medical University Cancer Institute and Hospital
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP